Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "Institute"

866 News Found

Max Healthcare announces Rs.1,000-cr foray into Pune with 450-bed super speciality hospital
Hospitals | December 19, 2025

Max Healthcare announces Rs.1,000-cr foray into Pune with 450-bed super speciality hospital

The state-of-the-art facility is expected to be commissioned over the next three years


Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
Clinical Trials | December 18, 2025

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint


FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Drug Approval | December 18, 2025

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis


Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board
People | December 17, 2025

Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute


KIMS Hospital Bengaluru commences operations at PES University campus
Hospitals | December 16, 2025

KIMS Hospital Bengaluru commences operations at PES University campus

The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital


Anil Koul joins Mankind Pharma as Group Chief Scientific Officer
People | December 15, 2025

Anil Koul joins Mankind Pharma as Group Chief Scientific Officer

More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline


Pfizer’s TUKYSA shows major benefit in first-line maintenance for metastatic breast cancer
Clinical Trials | December 12, 2025

Pfizer’s TUKYSA shows major benefit in first-line maintenance for metastatic breast cancer

The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA


Lilly drug cuts risk of disease progression or death by 80% in trial
Clinical Trials | December 11, 2025

Lilly drug cuts risk of disease progression or death by 80% in trial

The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study


Lilly to invest $6 billion in Huntsville manufacturing hub
News | December 10, 2025

Lilly to invest $6 billion in Huntsville manufacturing hub

The new site will produce next-generation synthetic medicine active pharmaceutical ingredients


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma